Clinical effectiveness secures BIMZELX as the first NICE expedited low risk fast track appraisal recommended treatment for moderate-to-severe plaque psoriasis1,2
BIMZELX is the first product to be recommended by NICE via a new approach to the fast-track appraisal process. The committee's findings can be found below.
NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2
Report adverse events
Help us to grow our resource the way you want it to grow.
Date of preparation: August 2021